These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 32793489)

  • 41. Diffuse midline glioma with H3 K27M mutation: a comparison integrating the clinical, radiological, and molecular features between adult and pediatric patients.
    Jiang H; Yang K; Ren X; Cui Y; Li M; Lei Y; Lin S
    Neuro Oncol; 2020 May; 22(5):e1-e9. PubMed ID: 31504810
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies.
    Persson ML; Douglas AM; Alvaro F; Faridi P; Larsen MR; Alonso MM; Vitanza NA; Dun MD
    Neuro Oncol; 2022 Sep; 24(9):1408-1422. PubMed ID: 35481923
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantation.
    Casalegno-Garduño R; Schmitt A; Spitschak A; Greiner J; Wang L; Hilgendorf I; Hirt C; Ho AD; Freund M; Schmitt M
    Int J Cancer; 2016 Apr; 138(7):1792-801. PubMed ID: 26519872
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Enhanced tumor immunity of WT1 peptide vaccination by interferon-β administration.
    Nakajima H; Oka Y; Tsuboi A; Tatsumi N; Yamamoto Y; Fujiki F; Li Z; Murao A; Morimoto S; Hosen N; Shirakata T; Nishida S; Kawase I; Isaka Y; Oji Y; Sugiyama H
    Vaccine; 2012 Jan; 30(4):722-9. PubMed ID: 22133512
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dendritic Cell-Based Adjuvant Vaccination Targeting Wilms' Tumor 1 in Patients with Advanced Colorectal Cancer.
    Shimodaira S; Sano K; Hirabayashi K; Koya T; Higuchi Y; Mizuno Y; Yamaoka N; Yuzawa M; Kobayashi T; Ito K; Koizumi T
    Vaccines (Basel); 2015 Dec; 3(4):1004-18. PubMed ID: 26690485
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
    May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CAR T cell therapies for diffuse midline glioma.
    Thomas BC; Staudt DE; Douglas AM; Monje M; Vitanza NA; Dun MD
    Trends Cancer; 2023 Oct; 9(10):791-804. PubMed ID: 37541803
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Epidemiology, Diagnostic Strategies, and Therapeutic Advances in Diffuse Midline Glioma.
    Miguel Llordes G; Medina Pérez VM; Curto Simón B; Castells-Yus I; Vázquez Sufuentes S; Schuhmacher AJ
    J Clin Med; 2023 Aug; 12(16):. PubMed ID: 37629304
    [No Abstract]   [Full Text] [Related]  

  • 49. The Wilms' tumor antigen is a novel target for human CD4+ regulatory T cells: implications for immunotherapy.
    Lehe C; Ghebeh H; Al-Sulaiman A; Al Qudaihi G; Al-Hussein K; Almohareb F; Chaudhri N; Alsharif F; Al-Zahrani H; Tbakhi A; Aljurf M; Dermime S
    Cancer Res; 2008 Aug; 68(15):6350-9. PubMed ID: 18676860
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers.
    Oka Y; Tsuboi A; Kawakami M; Elisseeva OA; Nakajima H; Udaka K; Kawase I; Oji Y; Sugiyama H
    Curr Med Chem; 2006; 13(20):2345-52. PubMed ID: 16918359
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].
    Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Use of (11)C-methionine PET parametric response map for monitoring WT1 immunotherapy response in recurrent malignant glioma.
    Chiba Y; Kinoshita M; Okita Y; Tsuboi A; Isohashi K; Kagawa N; Fujimoto Y; Oji Y; Oka Y; Shimosegawa E; Morita S; Hatazawa J; Sugiyama H; Hashimoto N; Yoshimine T
    J Neurosurg; 2012 Apr; 116(4):835-42. PubMed ID: 22242671
    [TBL] [Abstract][Full Text] [Related]  

  • 53. WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides.
    Brayer J; Lancet JE; Powers J; List A; Balducci L; Komrokji R; Pinilla-Ibarz J
    Am J Hematol; 2015 Jul; 90(7):602-7. PubMed ID: 25802083
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term survival of a patient with diffuse midline glioma in the pineal region: A case report and literature review.
    Ono T; Kuwashige H; Adachi JI; Takahashi M; Oda M; Kumabe T; Shimizu H
    Surg Neurol Int; 2021; 12():612. PubMed ID: 34992928
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Spinal Cord Diffuse Midline Glioma, H3K27M- mutant Effectively Treated with Bevacizumab: A Report of Two Cases.
    Yabuno S; Kawauchi S; Umakoshi M; Uneda A; Fujii K; Ishida J; Otani Y; Hattori Y; Tsuboi N; Kohno S; Noujima M; Toji T; Yanai H; Yasuhara T; Date I
    NMC Case Rep J; 2021; 8(1):505-511. PubMed ID: 35079510
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pediatric Diffuse Midline Gliomas H3 K27M-Mutant and Non-Histone Mutant Midline High-Grade Gliomas in Neurofibromatosis Type 1 in Comparison With Non-Syndromic Children: A Single-Center Pilot Study.
    Garibotto F; Madia F; Milanaccio C; Verrico A; Piccardo A; Tortora D; Piatelli G; Diana MC; Capra V; Garrè ML; Rossi A; Morana G
    Front Oncol; 2020; 10():795. PubMed ID: 32582540
    [No Abstract]   [Full Text] [Related]  

  • 57. Case Report: Five Adult Cases of H3K27-Altered Diffuse Midline Glioma in the Spinal Cord.
    Gu Q; Huang Y; Zhang H; Jiang B
    Front Oncol; 2021; 11():701113. PubMed ID: 34956856
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pediatric Diffuse Midline Gliomas: An Unfinished Puzzle.
    Di Ruscio V; Del Baldo G; Fabozzi F; Vinci M; Cacchione A; de Billy E; Megaro G; Carai A; Mastronuzzi A
    Diagnostics (Basel); 2022 Aug; 12(9):. PubMed ID: 36140466
    [TBL] [Abstract][Full Text] [Related]  

  • 59. WT1 epitope-specific IgG and IgM antibodies for immune-monitoring in patients with advanced sarcoma treated with a WT1 peptide cancer vaccine.
    Alzaaqi S; Naka N; Hamada K; Hosen N; Kanegae M; Outani H; Adachi M; Imanishi R; Morii E; Iwai M; Nakata J; Fujiki F; Morimoto S; Nakajima H; Nishida S; Tsuboi A; Oka Y; Sugiyama H; Oji Y
    Oncol Lett; 2022 Feb; 23(2):65. PubMed ID: 35069874
    [TBL] [Abstract][Full Text] [Related]  

  • 60. "Wilms Tumor Protein 1" (WT1) peptide vaccination-induced complete remission in a patient with acute myeloid leukemia is accompanied by the emergence of a predominant T-cell clone both in blood and bone marrow.
    Ochsenreither S; Fusi A; Busse A; Bauer S; Scheibenbogen C; Stather D; Thiel E; Keilholz U; Letsch A
    J Immunother; 2011 Jan; 34(1):85-91. PubMed ID: 21150716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.